AmDen Pharmaceuticals Denmark ApS: Financial statements 2022
CVR: 42045403
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
AmDen Pharmaceuticals Denmark ApS (CVR 42045403) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -6,788 and a net result of DKK -14,929 compared with DKK 583,562 the year before. Equity in the 2022 report amounted to DKK 35,071. The solvency ratio was 83%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -6,788
- Profit/Loss
- DKK -14,929
- Equity
- DKK 35,071
- Total Assets
- DKK 42,251
- Employees
- 1
Official annual report
Keep an eye on AmDen Pharmaceuticals Denmark ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
AmDen Pharmaceuticals Denmark ApS has published its annual report for 2021. Gross profit came to DKK 750,332, and the net result was DKK 583,562.
About AmDen Pharmaceuticals Denmark ApS
AmDen Pharmaceuticals Denmark ApS is a Danish company of the type Anpartsselskab based in Køge, founded in 2021. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Flemming Dyremose and Mikael Søndergaard Thomsen. The company is owned by Thomsen Pharma ApS and Flandy Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -7,514 and a net result of DKK -4,907 compared with DKK -7,596 the year before. Equity in the 2025 report amounted to DKK 17,994.